림프종과 골수종 환자에서 자가 조혈모세포 이식술의 현실 세계 경험
Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The first autologous peripheral blood stem cell transplantation (ASCT) in Korea was performed for a small-cell lung cancer patient at Asan Medical Center (AMC) in 1993. Recently, lymphoma and myeloma have been the main indications; there has been progress in the treatments for these lymphoid malignancies. We explored the real-world experience of ASCT for lymphoma and myeloma at AMC over a 25-year period. Methods: We used the AMC ASCT registry, which has collected ASCT data prospectively since January 1993. Data for Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma patients were analyzed. Patients transplanted up to December 2018 were included to assess adequate survival data. The ASCT time period was divided arbitrarily into 1994-1999, 2000-2009, and 2010-2018. In cases of multiple myeloma, we analyzed the 1st ASCT data only. Results: Survival of these lymphoid malignancy patients after ASCT has progressively improved. The increase in survival may be related to advances in various medical skills supporting ASCT. However, overall survival has improved much more than progression-free survival. This suggests that better salvage therapies after ASCT failure have mainly affected the improvement in overall survival. The hematopoietic cell transplantation-specific comorbidity index could not be used as a survival indicator in this analysis. Conclusions: This real-world experience study showed that the survival of lymphoid malignancy patients treated with ASCT has improved over the past 25 years.
Abstract
Background/Aims: The first autologous peripheral blood stem cell transplantation (ASCT) in Korea was performed for a small-cell lung cancer patient at Asan Medical Center (AMC) in 1993. Recently, lymphoma and myeloma have been the main indications; there has been progress in the treatments for these lymphoid malignancies. We explored the real-world experience of ASCT for lymphoma and myeloma at AMC over a 25-year period. Methods: We used the AMC ASCT registry, which has collected ASCT data prospectively since January 1993. Data for Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma patients were analyzed. Patients transplanted up to December 2018 were included to assess adequate survival data. The ASCT time period was divided arbitrarily into 1994-1999, 2000-2009, and 2010-2018. In cases of multiple myeloma, we analyzed the 1st ASCT data only. Results: Survival of these lymphoid malignancy patients after ASCT has progressively improved. The increase in survival may be related to advances in various medical skills supporting ASCT. However, overall survival has improved much more than progression-free survival. This suggests that better salvage therapies after ASCT failure have mainly affected the improvement in overall survival. The hematopoietic cell transplantation-specific comorbidity index could not be used as a survival indicator in this analysis. Conclusions: This real-world experience study showed that the survival of lymphoid malignancy patients treated with ASCT has improved over the past 25 years.
참고문헌 (24)
- Goodman JW, "Evidence for stem cells in the peripheral blood of mice", Blood, 19, pp.702~714 (1962)
- Barr RD, "Hemopoietic stem cells in human peripheral blood", Science, 190, pp.284~285 (1975)
- Goldman JM., "Autografting cryopreserved buffy coat cells for chronic granulocytic leukaemia in transformation", Exp Hematol., 7(Suppl 5), pp.389~397 (1979)
- Kessinger A, "Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy", Blood, 71, pp.723~727 (1988)
- Inwards D, "Peripheral blood stem cell transplantation : historical perspective, current status, and prospects for the future", Transfus Med Rev, 6, pp.183~190 (1992)
- Sorror ML, "Hematopoietic cell transplantation(HCT)-specific comorbidity index : a new tool for risk assessment before allogeneic HCT", Blood, 106, pp.2912~2919 (2005)
- Chao NJ, "Bone marrow transplantation. Part II--autologous", West J Med, 152, pp.46~51 (1990)
- Passweg JR, "Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America", Clin Transpl., pp.117~127 (1995)
- Horowitz MM, "An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation", Curr Opin Hematol, 4, pp.395~400 (1997)
- Cho SH, "High dose cyclophosphamide, thiotepa, and carboplatin followed by autologous peripheral stem cell rescue in patients with responsive metastatic or high-risk primary breast cancer", J Korean Cancer Assoc, 30, pp.100~105 (1998)
- Hee Jung Sohn, "High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) Followed by Autologous Stem-Cell Transplantation for Metastatic Breast Cancer Patients: A 6- Year Follow-Up Result", Cancer Research and Treatment, 37(1), pp.24~30 (2005), 대한암학회
- Hee-Jung Sohn, "High-Dose Chemotherapy of Cyclophosphamide, Thiotepa and Carboplatin (CTCb) followed by Autologous Stem-Cell Transplantation as a Consolidation for Breast Cancer Patients with ..", Cancer Research and Treatment, 37(3), pp.137~142 (2005), 대한암학회
- Bezwoda WR, "High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer : a randomized trial", J Clin Oncol, 13, pp.2483~2489 (1995)
- Howard DH, "Abandonment of high-dose chemotherapy", hematopoietic cell transplants for breast cancer following negative trial results, 2011, pp.46, 1762~1777
- Jae-LyunLee, "The Efficacy of High-dose Melphalan with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma", Yonsei Medical Journal, 44(5), pp.800~810 (2003), 연세대학교의과대학
- 고옥배, "Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study", The Korean Journal of Internal Medicine, 20(3), pp.237~242 (2005), 대한내과학회
- Cheolwon Suh, "Prognostic Factors in Non-Hodgkin’s Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center Experience", Cancer Research and Treatment, 37(5), pp.294~301 (2005), 대한암학회
- Kim MK, "High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma : complete response at transplant predicts survival", Ann Hematol, 86, pp.435~442 (2007)
- D'Souza A, "Current use of and trends in hematopoietic cell transplantation in the United States", Biol Blood Marrow Transplant., 26, pp.e177~e182 (2020)
- McCarthy PL Jr, "Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005 : significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age", Biol Blood Marrow Transplant, 19, pp.1116~1123 (2013)
- "The US Summary Slides - HCT Trends and Survival Data" (2020)[URL]
- Hyung J, "Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma", Ann Hematol, 98, pp.1657~1664 (2019)
- "미국 의사들도 깜짝 놀란 혈액암 치료법: 서울아산병원 서철원 교수, 자가 조혈모세포 이식 1000회" (2017)[URL]
- Kessinger A, "The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies", Blood, 77, pp.211~213 (1991)